Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Renal injury is one of the most common clinical manifestations of patients with hyperuricaemia/gout. The precise pathophysiological mechanism(s) for the renal injury is still unknown. Furthermore, it is also unclear whether the clinical therapies (e.g., colchicine and febuxostat) could prevent its progression or not. Lipids are involved in almost all of important biological processes and play critical roles in maintaining the renal functions. Herein, shotgun lipidomics was performed for class-targeted lipid analysis of cellular lipidomes in renal tissue of a gouty model induced by combination of monosodium urate crystals injection and high-fat diet feeding with/without treatment with either colchicine or febuxostat. Serum uric acid (UA), proinflammatory cytokines (i.e., TNF-α and IL-6), xanthine oxidase activity, footpad swelling, and pain threshold were determined to evaluate the gouty severity. Renal histopathological changes, blood urea nitrogen, creatinine, and kidney index were used to reflect renal injury. Lipidomics analysis revealed that altered triacylglycerol (TAG) profile, impaired mitochondrial function resulted by decreased tetra 18:2 cardiolipin, reduced 4-hydroxyalkenal (HNE) species, and elevated lysophospholipids were already present in the kidneys at early stage of renal injury, probably contributing to its occurrence and development. In addition to significantly reduce the UA level and relief the gouty severity, treatment with either colchicine or febuxostat could restore HNE bioavailability, thereby delaying the progression of renal injury. However, both of them could not recover the altered TAG profile and the impaired mitochondrial function, indicating that treatment with either of them could not completely prevent the development of renal injury in the gouty model.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188924PMC
http://dx.doi.org/10.3389/fmolb.2023.1190683DOI Listing

Publication Analysis

Top Keywords

renal injury
24
colchicine febuxostat
12
renal
9
lipidomics analysis
8
model induced
8
induced combination
8
crystals injection
8
injection high-fat
8
high-fat diet
8
diet feeding
8

Similar Publications

Metabolic Syndrome Is Associated with the Prognosis in Elderly Critically Ill Patients with Acute Kidney Injury.

Diabetes Metab Syndr Obes

September 2025

Department of Nephrology, Wuyi County First People's Hospital, Jinhua City, Zhejiang Province, People's Republic of China.

Purpose: Metabolic syndrome (MetS) is linked to adverse outcomes in chronic diseases, but its impact on acute kidney injury (AKI) in elderly critically ill patients remains unclear. This study aimed to evaluate the association between MetS and 90-day mortality in this population.

Patients And Methods: A retrospective analysis included 774 elderly patients (≥65 years) with AKI admitted to the ICU from January 2022 to December 2023.

View Article and Find Full Text PDF

Acute kidney injury (AKI) is a group of common clinical syndromes characterized by a rapid decline in renal function over a short period of time. At present, the treatment methods are limited, and research is needed to identify drugs that could alleviate renal ischemia-reperfusion (I/R) injury. Tetramethylpyrazine (TMP) is a bioactive alkaloid extracted from the Chinese herbal medicine Chuanxiong.

View Article and Find Full Text PDF

Organ transplantation faces critical challenges, including donor shortages, suboptimal preservation, ischemia-reperfusion injury (IRI), and immune rejection. Nanotechnology offers transformative solutions by leveraging precision-engineered materials to enhance graft viability and outcomes. This review highlights nanomaterials' roles in revolutionizing organ preservation.

View Article and Find Full Text PDF

Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerulonephritis globally, is characterized by mesangial IgA deposition and heterogeneous clinical trajectories. Historically, management relied on renin-angiotensin system inhibition and empirical immunosuppression, yet high lifetime kidney failure risk persists despite optimized care. This review synthesizes advances in molecular pathogenesis, highlighting how the traditional multi-hit hypothesis-while foundational for targeted therapy development-fails to capture IgAN's recurrent, self-amplifying nature.

View Article and Find Full Text PDF